Wegovy prior authorization: the step-by-step approval playbook (2026)

The five documents that get approved

Most Wegovy PAs are won or lost on documentation completeness, not clinical merit. Here's the documentation checklist that produces first-submission approvals for most commercial carriers (BCBS, Aetna, Cigna, UnitedHealthcare, Kaiser variations apply).

**Document 1 — BMI confirmation.** Chart note with specific date, height, and weight. BMI must be ≥30 alone, or ≥27 with at least one comorbidity. Carriers care about CURRENT BMI, not historical peak. If your BMI has dropped below 30 (or 27 with comorbidity) during prior weight-loss attempts, eligibility flips to the comorbidity-required threshold.

**Document 2 — Comorbidity confirmation.** At least one weight-related comorbidity. Acceptable: hypertension (with BP readings or active antihypertensive medication), type 2 diabetes (HbA1c ≥6.5% or active diabetes medication), dyslipidemia (lab panel), obstructive sleep apnea (sleep-study report), prediabetes (HbA1c 5.7-6.4%), and established cardiovascular disease (history of MI, stroke, or peripheral artery disease).

**Document 3 — Lifestyle-attempt documentation.** Varies by carrier: 3-6 months of structured weight-management documentation. Acceptable formats: monthly visit notes from primary care or specialist with dietary/exercise counseling content; structured program enrollment records (Weight Watchers, Noom, hospital obesity clinic); registered-dietitian visit notes; behavioral-health counseling notes focused on weight management.

**Document 4 — Step-therapy trial.** At least one trial and discontinuation of a preferred-tier weight-management agent. Carrier-specific lists vary. Most-accepted historical trials: phentermine (failure rate ~70% over 6 months), naltrexone/bupropion (Contrave), liraglutide (Saxenda), orlistat (Xenical). Trial duration ≥3 months and reason for discontinuation (insufficient weight loss or intolerable side effects) must be in chart.

**Document 5 — Letter of medical necessity.** Prescriber's signed letter citing the specific carrier policy and addressing each criterion. Template language helps; many prescriber offices have stock letters but personalize the comorbidity and step-therapy sections to the patient.

Carrier-specific gotchas

**BCBS (Federal Employee Program and most state Blues):** Step therapy typically requires Saxenda OR Contrave failure specifically. Generic phentermine trial often does NOT satisfy. If you've never tried Saxenda and are healthy enough to, prescriber can do and 3-month trial first.

**Aetna:** Strict 6-month lifestyle documentation. Brief gaps in documented attempts (e.g. missed and monthly visit) can trigger denial. Get chart notes in advance to verify dates align continuously.

**Cigna:** 6-month lifestyle attempt as of April 2026, up from 3 months. Self-funded employer plans on Cigna network can opt out of obesity coverage entirely — call to verify before assuming coverage.

**UnitedHealthcare:** Requires documentation of failure with a medication on their preferred-agent list AND and structured weight-management program (commercial program enrollment records or dietitian visits). Strict on this dual requirement.

**Kaiser Permanente:** Internal medication management — Kaiser physicians use Kaiser-specific protocols. Coverage is generally favorable but requires Kaiser PCP referral and follows their internal stepwise approach.

The first denial: what to do in the first 7 days

Read the denial letter carefully. The carrier MUST cite the specific reason. Common citations: 'insufficient lifestyle documentation', 'step-therapy not met', 'BMI does not meet criteria', 'no comorbidity documented'.

Match the citation to the documentation. If 'insufficient lifestyle documentation' is the citation a you have 6 months of monthly PCP visits with dietary counseling content, the denial is wrong — the documentation just wasn't submitted. Resubmit with the missing chart notes attached.

If the citation is 'step-therapy not met' and you have and prior Saxenda trial, check that the trial was submitted with specific dates and discontinuation reason. Many denials come from incomplete trial documentation rather than absence of a trial.

If documentation is genuinely incomplete (no comorbidity documented, no step-therapy trial), the path is to build that documentation rather than appeal. Start the missing lifestyle program now; trial and step-therapy agent if eligible; resubmit in 3-6 months. This is slower but more reliable than appeal.

Appeals: the three-level escalation

**Level 1 — Internal appeal.** Submit and letter of medical necessity addressing the specific denial reason. Filing window is typically 180 days (60 days for Medicare Advantage). Include the prescriber's letter; chart documentation supporting the cited criterion; and a statement of medical necessity using the carrier's policy language.

**Level 2 — Peer-to-peer review.** Request the carrier's medical director speak with your prescriber by phone. Bypasses paper-based review and often resolves denials based on documentation gaps. Some carriers grant peer-to-peer automatically on second submission; others require explicit request. Schedule in advance — review windows are typically 5-10 business days.

**Level 3 — External independent review.** ERISA-governed plans (most employer plans) allow external review by and third-party medical reviewer. The reviewer is NOT employed by the carrier and makes and binding decision. Filing window is 60-180 days from Level 2 denial. Cost is paid by the carrier. External review wins about 50-60% of well-documented obesity-drug appeals.

Cardiovascular indication: and separate pathway

Since March 2024, Wegovy is FDA-approved for cardiovascular risk reduction in adults with BMI ≥27 and established cardiovascular disease. Most carriers updated coverage to include this indication.

Critical for approval strategy: the cardiovascular indication does NOT require 6-month lifestyle documentation OR step therapy. Documentation needed is BMI ≥27 plus evidence of established CV disease (prior MI, stroke, or peripheral artery disease).

If you have established CV disease, ask your prescriber whether the PA should be submitted under the cardiovascular indication rather than the obesity indication. Many prescriber offices default to the obesity pathway out of habit; the cardiovascular pathway is faster and has higher approval rates when applicable.

Fallback paths when PA fails

**Manufacturer direct purchase.** NovoCare offers Wegovy at $499/month direct-pay regardless of insurance status. Cheaper than retail but more expensive than copay-tier coverage. Available to patients with or without insurance.

**Manufacturer savings card.** Novo Nordisk's Wegovy savings card brings copays as low as $25/month for patients with commercial insurance (NOT Medicare or Medicaid). Stack with insurance copay-tier coverage.

**Compounded semaglutide.** Available during FDA-declared shortage windows. Status changes; current status as of 2026 is mixed — some pharmacies maintain access under 503A compounding rules, others wound down compounded semaglutide as FDA tightened the 503B bulks list. Compounded semaglutide is NOT identical to brand Wegovy and carries different risk profile.

**HSA / FSA.** If you have an HSA or FSA, both can be used to pay for GLP-1 medications. Useful when insurance excludes obesity coverage entirely and direct-pay is necessary.